Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,409 | $11.92 | 48,163 | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,409 | -- | -- | |
| Aug 06, 2013 | SVP, GM - Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,409 | -- | 17,409 | |
| Jul 18, 2018 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,469 | -- | 129,286 | |
| Jul 27, 2007 | Executive VP and COO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,500 | -- | 17,500 | |
| Aug 06, 2013 | SVP, GM - International | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,531 | -- | 17,531 | |
| Sep 14, 2020 | SVP/GM, VIT | Form 3 | Initial Statement of Beneficial Ownership of Securities | 17,640 | -- | -- | |
| Aug 06, 2013 | SVP, Business Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,714 | -- | 17,714 | |
| Feb 13, 2015 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,100 | $15.27 | 46,801 | |
| Feb 13, 2015 | SVP, GM - Oncology | Form 4 | Open market or private sale of non-derivative or derivative security | 18,100 | $18.53 | 28,701 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.